Pharming Group Net Worth
Pharming Group Net Worth Breakdown | PHAR |
Pharming Group Net Worth Analysis
Pharming Group's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pharming Group's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pharming Group's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pharming Group's net worth analysis. One common approach is to calculate Pharming Group's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pharming Group's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pharming Group's net worth. This approach calculates the present value of Pharming Group's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pharming Group's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pharming Group's net worth. This involves comparing Pharming Group's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pharming Group's net worth relative to its peers.
Enterprise Value |
|
To determine if Pharming Group is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pharming Group's net worth research are outlined below:
| Pharming Group NV generated a negative expected return over the last 90 days | |
| Pharming Group NV has high historical volatility and very poor performance | |
| Pharming Group NV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 245.32 M. Net Loss for the year was (9.55 M) with profit before overhead, payroll, taxes, and interest of 188.06 M. | |
| Pharming Group NV currently holds about 189.96 M in cash with (17.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91. | |
| Pharming Group NV has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Pharming Group to participate in November investor conference |
Pharming Group uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pharming Group NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pharming Group's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Pharming Group's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pharming Group is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pharming Group NV backward and forwards among themselves. Pharming Group's institutional investor refers to the entity that pools money to purchase Pharming Group's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Silverberg Bernstein Capital Management Llc | 2024-09-30 | 41.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.6 K | Ubs Group Ag | 2024-06-30 | 789 | Advisor Group Holdings, Inc. | 2024-06-30 | 568 |
Follow Pharming Group's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 510.8 M.Market Cap |
|
Project Pharming Group's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.05) | (0.05) |
When accessing Pharming Group's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pharming Group's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pharming Group's profitability and make more informed investment decisions.
Evaluate Pharming Group's management efficiency
Pharming Group NV has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0818) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Asset Turnover is relatively stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.30 | 0.29 | |
| Tangible Book Value Per Share | 0.19 | 0.35 | |
| Enterprise Value Over EBITDA | 159.08 | 167.04 | |
| Price Book Value Ratio | 3.42 | 3.07 | |
| Enterprise Value Multiple | 159.08 | 167.04 | |
| Price Fair Value | 3.42 | 3.07 | |
| Enterprise Value | 792.4 M | 832 M |
Evaluating the management effectiveness of Pharming Group allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Pharming Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 1.623 | Revenue 285.7 M | Quarterly Revenue Growth 0.122 | Revenue Per Share 4.38 | Return On Equity (0.08) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pharming Group insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pharming Group's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pharming Group insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camden Partners Strategic Fund Ii A Lp over three months ago Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3 |
Pharming Group Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
6K | 24th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify |
Pharming Group Earnings per Share Projection vs Actual
Pharming Group Corporate Management
| Bruno Giannetti | Consultant | Profile | |
| Susanne Embleton | Investor Manager | Profile | |
| Jeroen Wakkerman | Chief Officer | Profile | |
| Ruud Outersterp | Chief Officer | Profile | |
| Stephen Toor | Chief Americas | Profile | |
| Anurag Relan | Chief Officer | Profile |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.